Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it introduces the cobas® HDV test for use on the cobas® 5800/6800/8800 systems, a diagnostic tool for the detection and quantification of Hepatitis D Virus (HDV) RNA, in countries accepting the CE mark. Available on the industry-leading cobas 5800/6800/8800 systems, Roche aims to help healthcare providers in identifying patients and monitoring their care more effectively alongside newly available treatments.

To the cheers of blood centers, the US Food and Drug Administration said this week that it plans to eliminate a requirement to screen donated blood with hepatitis B virus surface antigen testing when two other testing methods are also used.

A team has identified cell type-specific gene expression signatures in blood samples from individuals with acute SARS-CoV-2 infections that appeared to predict the risk and types of long-term symptoms they may experience

Roche’s new test is the first available immunoassay that allows for simultaneous, independent determination of the hepatitis C virus antigen and antibody status.

Roche announced on Monday that its Elecsys HCV Duo test for hepatitis C virus (HCV) received CE marking, and it is launching in countries accepting the regulatory approval.

On May 6, BGI Genomics Co.,Ltd. announced that it will rapidly provide a comprehensive detection and screening program for children with acute hepatitis of unknown cause.